CEN Biotech, Inc. (CENBF)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
May 2, 2025, 2:12 PM EDT
CEN Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | 2013 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '22 Sep 30, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | 2013 - 2016 |
| Revenue | 1.03 | 0.63 | - | - | - | - | Upgrade
|
| Gross Profit | 1.03 | 0.63 | - | - | - | - | Upgrade
|
| Selling, General & Admin | 17.28 | 18.25 | 2.21 | 1.4 | 2.42 | 3.84 | Upgrade
|
| Operating Expenses | 2.35 | 18.25 | 2.21 | 2.58 | 3.1 | 11.61 | Upgrade
|
| Operating Income | -1.32 | -17.63 | -2.21 | -2.58 | -3.1 | -11.61 | Upgrade
|
| Interest Expense | -0.35 | -0.85 | -3.68 | -3.31 | -2.87 | -2.38 | Upgrade
|
| Interest & Investment Income | 0.13 | 0 | 0.01 | 0.01 | 0.01 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0.03 | -0.06 | -0.07 | 0.09 | -0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.17 | 0.97 | -0.66 | 0.29 | -0.39 | - | Upgrade
|
| EBT Excluding Unusual Items | -1.72 | -17.53 | -6.59 | -5.66 | -6.26 | -14.08 | Upgrade
|
| Merger & Restructuring Charges | -0.08 | -0.08 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | -0.14 | - | - | - | Upgrade
|
| Asset Writedown | - | - | - | - | -1.27 | - | Upgrade
|
| Other Unusual Items | -1.33 | -1.33 | 20.98 | - | - | - | Upgrade
|
| Pretax Income | -3.13 | -18.94 | 14.25 | -5.66 | -7.53 | -14.08 | Upgrade
|
| Income Tax Expense | -0.04 | -0.04 | - | - | - | - | Upgrade
|
| Net Income | -3.1 | -18.9 | 14.25 | -5.66 | -7.53 | -14.08 | Upgrade
|
| Net Income to Common | -3.1 | -18.9 | 14.25 | -5.66 | -7.53 | -14.08 | Upgrade
|
| Shares Outstanding (Basic) | 61 | 42 | 27 | 26 | 25 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 61 | 42 | 33 | 26 | 25 | 8 | Upgrade
|
| Shares Change (YoY) | 48.69% | 29.59% | 24.15% | 4.19% | 201.08% | 22.66% | Upgrade
|
| EPS (Basic) | -0.05 | -0.45 | 0.52 | -0.21 | -0.30 | -1.68 | Upgrade
|
| EPS (Diluted) | -0.05 | -0.45 | 0.45 | -0.21 | -0.30 | -1.68 | Upgrade
|
| Free Cash Flow | -0.59 | -0.36 | -0.34 | -0.87 | -1.73 | -2.34 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.03 | -0.07 | -0.28 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | - | - | - | - | Upgrade
|
| Operating Margin | -127.54% | -2811.72% | - | - | - | - | Upgrade
|
| Profit Margin | -299.69% | -3015.58% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -57.59% | -57.22% | - | - | - | - | Upgrade
|
| EBITDA | -0.89 | -17.16 | -1.77 | -2.14 | -2.66 | -11.19 | Upgrade
|
| D&A For EBITDA | 0.43 | 0.46 | 0.44 | 0.44 | 0.44 | 0.43 | Upgrade
|
| EBIT | -1.32 | -17.63 | -2.21 | -2.58 | -3.1 | -11.61 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.